SAN FRANCISCO (EGMN) - Early clinical trials of a new targeted oral drug called fostamatinib disodium show it to be highly active in non-Hodgkin's lymphomas that exhibit what is being described as an addiction to B-cell receptor signalling.Fostamatinib (also known as R788) inhibits a protein called SYK (spleen tyrosine kinase) that regulates the B-cell receptor's ability to send a survival signal to cancer cells. It produced significant responses in patients with diffuse large B-cell lymphoma (DLBCL)...